Tuesday, January 10, 2023 7:34:49 PM
Sounds like a drug dealer on the corner waiting for his buyer
I will never understand why he’s not cutting a license deal with big pharma. I don’t think many here realize how difficult it is to bring to market a drug and do it at scale. Fda looks at everything not just endpoints and trial data
Say the drug works and is approved. Frank has no ability to quickly hire a sales force, manufacturer with high quality standards for safety, packaging and distribute
If the drug works line up the big boys and collect the royalties almost risk free.
I will never understand why he’s not cutting a license deal with big pharma. I don’t think many here realize how difficult it is to bring to market a drug and do it at scale. Fda looks at everything not just endpoints and trial data
Say the drug works and is approved. Frank has no ability to quickly hire a sales force, manufacturer with high quality standards for safety, packaging and distribute
If the drug works line up the big boys and collect the royalties almost risk free.
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
